Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.
Frequently asked questions
What sector does Regen BioPharma Inc (RGBP) operate in?
Regen BioPharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Regen BioPharma Inc (RGBP) current stock price?
As of the latest data, Regen BioPharma Inc stock price is $0.00, with a previous close of $0.00.
What is Regen BioPharma Inc (RGBP) current market capitalization?
Regen BioPharma Inc market cap is approximately 167.53 thousand.
What is Regen BioPharma Inc (RGBP) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Regen BioPharma Inc (RGBP) EBITDA?
Regen BioPharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 33.28 thousand.
Does Regen BioPharma Inc (RGBP) pay dividends?
No. Regen BioPharma Inc does not pay a dividend.
What is Regen BioPharma Inc (RGBP) beta (volatility) score?
Regen BioPharma Inc has a beta of -0.328, indicating lower volatility than the overall market.
